BioCeramic Therapeutics Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioCeramic Therapeutics Ltd.
Stem-cell-related strategies may predominate these days in tissue engineering, but cell therapy companies know that providing the right microenvironment for nurturing tissue growth remains a difficult and essential challenge. Thus, start-ups remain committed to the developent of cellular matrices that provide the appropriate structure, environment, and bioactivity to encourage tissue growth. The four start-ups profiled in this issue represent a cross-section of strategies.
BioCeramic Therapeutics was formed around separate regenerative medicine technologies that it believes have broad potential. First up is a strontium containing glass-based material for use as a bone filler and a coating for metal implants used in various orthopedic and orthodontic procedures. The company is also developing a nanostructured synthetic extracellular matrix that could address the regeneration of hard and soft tissues, with the potential one day to allow almost any tissue to be grown.
Noteworthy news from medtech start-ups. In this issue: New Scaffolds for Tissue Engineering, with brief profiles of BioCeramic Therapeutics Ltd., Histogen Inc., Humacyte Inc., and Tissue Regenix. (Adapted from "Scaffolds in Tissue Engineering," START-UP, February 2008.)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Scaffolds in Tissue Engineering," features profiles of BioCeramic Therapeutics, Histogen, Humacyte and Tissue Regenix. Plus these Start-Ups Across Health Care: Braintact, CleveX, Coherex Medical and Lytix Biopharma.
- Implantable Devices
- Other Names / Subsidiaries
- Advanced Tissue Therapies Ltd.